Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial-Reference-Cited by-同舟云学术

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial

Published:2017-08-22 Issue:3 Volume:17 Page:441-448
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Webb David J.,Coll Blai,Heerspink Hiddo J. L.,Andress Dennis,Pritchett Yili,Brennan John J.,Houser Mark,Correa-Rotter Ricardo,Kohan Donald,Makino Hirofumi,Perkovic Vlado,Remuzzi Giuseppe,Tobe Sheldon W.,Toto Robert,Busch Robert,Pergola Pablo,Parving Hans-Henrik,de Zeeuw Dick

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

https://link.springer.com/article/10.1007/s40268-017-0201-0/fulltext.html

Reference22 articles.

1. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25(5):1083–93.

2. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9.

3. Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA. 2016;315(18):1975–88.